Foreign Bonds, Fres...
Health Care: Drugs
Regenerx Biopharmaceuticals Inc. (RGN: AMEX)
$0.23 -0.03 | -12.19%
12/22/10 - 03:59 PM ET
319.36K / 167.00K
Vol / Avg. Vol:0.26 / 0.26
Open / Prev. Close:0.23 - 0.27
Today's Range:0.22 - 0.79
52 Wk Range:-57.69%
Performance YTD:TheStreet Rating:
Portfolios with RGN
- Portfolio NameUser Type
- UserBeholden to All
- UserPART 5 JPMorgan 28th Annual...
- ContributorBarron's Insider Purchases ...
- UserR/D bio/pharm
- Userrahrah Portfolio 1
- UserStars of Yesterday
- Userdeanh@dsldata.com Portfolio 1
- UserRover96
- Userjoanie Portfolio 1
- UserThomas Gibson Portfolio
Latest RGN Headlines from TheStreet
- Biotech ETFs Rise on M&A Buzz 07.26.10 | 11:07 am
- Stock Offerings: Resource Capital 05.18.10 | 10:05 am
- Stock Offerings: Two Harbors 04.19.10 | 10:04 am
- Encorium Group, MDRNA: Early Volume Plays 04.05.10 | 08:04 am
- China Nuokang Bio-Pharmaceutical: China Watch
12.11.09 | 04:12 am - Movers Roundup: MCG Capital, Thomas & Betts 09.29.09 | 05:09 pm
- RegeneRx Jumps On Positive Preclinical Study Data 09.29.09 | 02:09 pm
- Biotech Mailbag: Bad CEOs Offer Lessons 12.19.08 | 11:12 am
- Thursday's Health Winners & Losers 12.28.06 | 01:12 pm
- Monday's Health Winners & Losers 09.11.06 | 04:09 pm
Press Releases for RGN
- First Patient Screened In Phase 2 Trial With RegeneRx’s RGN-259 For Dry Eye Syndrome - Business Wire 12.22.10 | 09:12 am
- RegeneRx’s Scientific Advisory Board Member Receives 2011 Camras Award - Business Wire 12.20.10 | 10:12 am
- RegeneRx Receives Mexican Patent For The Use Of TB4 For Prevention And Treatment Of Cardiac Damage - Business Wire 12.09.10 | 10:12 am
- RegeneRx Receives Australian Patent Using TB4 To Protect Against Biological, Chemical And Toxic Agents - Business Wire 12.01.10 | 10:12 am
- Researchers Identify Potential Thymosin Beta 4 Receptor - Business Wire 11.30.10 | 01:11 pm
- RegeneRx Receives Australian Patent Using Tβ4 For Treatment Of Gastrointestinal Disorders - Business Wire 11.17.10 | 09:11 am
- RegeneRx President And CEO To Present At Maxim Group Growth Conference - Business Wire 11.16.10 | 02:11 pm
- RegeneRx Reports Positive Results Of Preclinical Dry Eye Study - Business Wire 11.02.10 | 07:11 am
- RegeneRx Receives Non-compliance Notice From NYSE Amex; Intends To Request Hearing - Business Wire 11.01.10 | 04:11 pm
- RegeneRx Awarded $733,438 From U.S. Government Under The Patient Protection And Affordable Care Act - Business Wire 11.01.10 | 12:11 pm
Partner Headlines for RGN
- Researchers Identify Potential Thymosin Beta 4 Receptor - Benzinga 11.30.10 | 01:11 pm
